Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...
Hosted on MSN
What is an absence seizure?
(NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million people worldwide are diagnosed with epilepsy, and seizures are the main ...
Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence ...
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.
Older adults who have a heart attack may be more likely to develop epilepsy later in life, according to a study published in ...
Members of Bright Minds' leadership team will review the therapeutic rationale for BMB-101 and discuss the Company’s BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, ...
NEW YORK, Sept. 12, 2024 /CNW/ - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback